New Blood Test Predicts Chemotherapy Benefit for Colorectal Cancer
A personalized blood test measuring circulating tumor DNA (ctDNA) can identify colorectal cancer patients who benefit most from adjuvant chemotherapy after liver metastasis surgery. According to the Phase II GALAXY study presented at the ESMO Gastrointestinal Cancers Congress 2026, patients with detectable ctDNA after surgery saw overall survival rates of 65% with chemotherapy, compared to … Read more